Literature DB >> 22290760

High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients.

Caroline Scholtes1, Christophe Ramière, Dominique Rainteau, Laure Perrin-Cocon, Claude Wolf, Lydie Humbert, Martine Carreras, Aurélie Guironnet-Paquet, Fabien Zoulim, Ralf Bartenschlager, Vincent Lotteau, Patrice André, Olivier Diaz.   

Abstract

UNLABELLED: Hepatitis C virus (HCV) particles associate viral and lipoprotein moieties to form hybrid lipoviral particles (LVPs). Cell culture-produced HCV (HCVcc) and ex vivo-characterized LVPs primarily differ by their apolipoprotein (apo) B content, which is low for HCVcc, but high for LVPs. Recombinant nucleocapsid-free subviral LVPs are assembled and secreted by apoB-producing cell lines. To determine whether such subviral particles circulate in HCV-infected individuals, LVPs complexed with immunoglobulin were precipitated with protein A from low-density plasma fractions of 36 hepatitis C patients, and their lipid content, apolipoprotein profile, and viral composition were determined. HCV RNA in LVPs was quantified and molar ratios of apoB and HCV genome copy number were calculated. LVPs lipidome from four patients was determined via electrospray ionization/tandem mass spectrometry. Protein A-purified LVPs contained at least the envelope glycoprotein E2 and E2-specific antibodies. LVPs were present in every patient and were characterized by high lipid content, presence of apolipoproteins characteristic of triglyceride-rich lipoproteins (TRLs), HCV RNA, and viral glycoprotein. Importantly, save for four patients, LVPs fractions contained large amounts of apoB, with on average more than 1 × 10(6) apoB molecules per HCV RNA genome. Because there is one apoB molecule per TRL, this ratio suggested that most LVPs are nucleocapsid-free, envelope glycoprotein-containing subviral particles. LVPs and TRLs had similar composition of triacylglycerol and phospholipid classes.
CONCLUSION: LVPs are a mixed population of particles, comprising predominantly subviral particles that represent a distinct class of modified lipoproteins within the TRL family.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22290760     DOI: 10.1002/hep.25628

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  24 in total

1.  Plasma triglyceride levels may modulate hepatitis C viral replication.

Authors:  David H Van Thiel; Magdalena George; Bashar M Attar; Giuliano Ramadori; Niculae Ion-Nedelcu
Journal:  Dig Dis Sci       Date:  2014-02-22       Impact factor: 3.199

2.  High level of serum cholesteryl ester transfer protein in active hepatitis C virus infection.

Authors:  Kenichi Satoh; Tomohisa Nagano; Nobuyoshi Seki; Yoichi Tomita; Yuta Aida; Tomonori Sugita; Munenori Itagaki; Satoshi Sutoh; Hiroshi Abe; Yoshio Aizawa
Journal:  World J Hepatol       Date:  2016-02-18

3.  The strange and critical intersection of hepatitis C and lipoprotein metabolism: "C-zing" the oil.

Authors:  Stephen Caldwell; Kyle L Hoehn; Young S Hahn
Journal:  Hepatology       Date:  2012-12-12       Impact factor: 17.425

Review 4.  Chronic hepatitis C virus infection and lipoprotein metabolism.

Authors:  Yoshio Aizawa; Nobuyoshi Seki; Tomohisa Nagano; Hiroshi Abe
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

5.  The missing pieces of the HCV entry puzzle.

Authors:  Sarah C Ogden; Hengli Tang
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

6.  Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells.

Authors:  Baptiste Jammart; Maud Michelet; Eve-Isabelle Pécheur; Romain Parent; Birke Bartosch; Fabien Zoulim; David Durantel
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

Review 7.  Lipids and HCV.

Authors:  M F Bassendine; D A Sheridan; S H Bridge; D J Felmlee; R D G Neely
Journal:  Semin Immunopathol       Date:  2012-10-31       Impact factor: 9.623

Review 8.  Hepatitis C Virus Uses Host Lipids to Its Own Advantage.

Authors:  Malgorzata Sidorkiewicz
Journal:  Metabolites       Date:  2021-04-27

Review 9.  Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease.

Authors:  Daniel J Felmlee; Mohamed Lamine Hafirassou; Mathieu Lefevre; Thomas F Baumert; Catherine Schuster
Journal:  Viruses       Date:  2013-05-23       Impact factor: 5.048

10.  Serum lipoprotein profiles and response to pegylated interferon plus ribavirin combination therapy in patients with chronic HCV genotype 1b infection.

Authors:  Yoshio Aizawa; Noritomo Shimada; Hiroshi Abe; Nobuyoshi Seki; Yuta Aida; Haruya Ishiguro; Makiko Ika; Keizo Kato; Akihito Tsubota
Journal:  Hepat Mon       Date:  2013-05-27       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.